頁籤選單縮合
題名 | 概述血色素沉著症=Haemochromatosis |
---|---|
作者 | 郭廷濠; Kuo, Ting-hao; |
期刊 | 藥學雜誌 |
出版日期 | 20190900 |
卷期 | 35:3=140 2019.09[民108.09] |
頁次 | 頁53-56 |
分類號 | 415.6 |
語文 | chi |
關鍵詞 | 血色素沉著症; 青銅色糖尿病; 靜脈切開術; C282Y; Hepcidin; |
中文摘要 | 血色素沉著症係為一鐵質平衡障礙疾病,本文主要探討遺傳性血色素沉著症,其 主要為第六條染色體短壁 HFE 基因發生異常所致之體染色體隱性疾病,會干擾肝抑鐵 素對鐵質的調控。由於病生理致病機轉更加明瞭,肝抑鐵素亦在鐵質調控上扮演著十 分重要的角色,目前治療上仍以靜脈切開術為主流,但肝抑鐵素相似物之治療在未來 仍十分具有發展潛力。 |
英文摘要 | Haemochromatosis is defined as a iron homeostasis disorder, in this paper we focus on genetic haemochromatosis. Mainly genetic haemochromatosis patients are HFE gene related haemochromatosis which mutate on chromosome 6, this mutation will cause hepcidin deficiency. To date, there is more understanding about the pathophysiology of haemochromatosis, disclose that hepcidin plays an important role in the disease. Current therapies are phlebotomy and chelation therapy, but still insufficient, hepcidin therapy, a novel therapy, will provide new hope for treating haemochromatosis. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。